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Abstract
Background—Increasing evidence suggests that stress system activation after burn injury may
contribute to burn-related pain. If this is the case, then genetic variations influencing the function
of important stress system components, such as the enzyme catechol-O-methyltransferase
(COMT), may predict pain severity after thermal burn injury.
Methods—We evaluated the association between COMT genotype and pain intensity in 57
individuals hospitalized after thermal burn injury. Consenting participants at four burn centers
were genotyped and completed daily 0-10 numeric rating scale pain assessments on two
consecutive days including evaluation of waking, least, and worst pain. The association between
COMT genotype and individual pain outcomes was calculated using a linear mixed model
adjusting for sociodemographic and burn injury characteristics.
Results—Overall pain (combination of least, worst, and waking pain scores) was significantly
higher in patients with a COMT pain vulnerable genotype (6.3 (.4) vs. 5.4 (.4), p=.037).
Individuals with a COMT pain vulnerable genotype also had significantly higher “least pain”
scores (3.8 (.5) vs. 2.6 (.4), p=.017) and significantly higher pain on awakening (6.8 (.5) vs. 5.3 (.
4), p=.004). Differences in worst pain according to genotype group were not significant. COMT
pain vulnerable genotype was a stronger predictor of overall pain severity than burn size, burn
depth, or time from admission to pain interview assessment.
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Conclusions—These findings suggest that genetic factors influencing stress system function
may have an important influence on pain severity after burn injury. Further studies of genetic
predictors of pain after burn injury are needed.
Keywords
catechol-O-methyltransferase; burn; pain; stress
Introduction
Despite major advances in burn care, most of the ∼50,000 patients admitted to US burn
centers each year1 experience substantial pain during hospitalization.2,3 It is often assumed
that burn pain intensity is primarily determined by injury characteristics such as burn size
and depth. However, available data indicate that burn characteristics are not strong
predictors of burn-related pain.4-6 This suggests that other, as yet unidentified factors may
play an important role in determining the pain experience of burn patients. The identification
of such factors may create new opportunities to improve burn care.
Increasing evidence suggests that stress response system activation after burn injury may
contribute to burn-related pain. In addition to causing direct tissue damage, a burn injury is a
potent stressor which activates the sympathetic nervous system and adrenomedullary
hormonal system, resulting in the release of catecholamines.7 Results of both animal and
human studies have demonstrated that catecholamine levels influence pain sensitivity.8-13 If
this is the case, then genetic variations affecting catecholamine levels may predict individual
variations in pain severity after burn injury.
One stress system component influencing catecholamine levels is the enzyme catechol-O-
methyltransferase (COMT). COMT is the primary enzyme that metabolizes catecholamines,
including epinephrine, norepinephrine, and dopamine.14 Genetic variations in the COMT
gene (COMT diplotype) influencing COMT enzyme function have been found to predict
acute pain sensitivity in experimental settings.15 In addition, classifying patients by COMT
diplotype into those with or without a “COMT pain vulnerable genotype” has been shown to
predict musculoskeletal pain severity and psychological distress after minor injury.16
However, to our knowledge the potential contribution of genetic variations influencing the
function of important stress system components such as COMT to pain after major injury
has never been examined. In this study we examined the association between COMT pain
vulnerable genotype and pain intensity among patients admitted to the hospital after thermal
burn injury. We hypothesized that hospitalized burn patients with a COMT pain vulnerable
genotype would experience increased pain in comparison to those without this genotype. In
addition, we compared the strength of association between COMT genotype and acute burn
pain with the strength of association between several commonly assessed burn injury
characteristics and acute burn pain. Because of increasing evidence that individual
neurobiology has an influence on pain outcomes comparable to/greater than injury
severity,16 we hypothesized that COMT genotype would have an influence on pain as great
or greater than characteristics of the burn injury.
Methods
Patients presenting to four burn centers (Jaycee Burn Center, University of North Carolina,
Chapel Hill, NC; The Burn Center, Washington Hospital Center, Washington, DC; Wake
Forest University Baptist Burn Center, Wake Forest, NC; Nathan Speare Regional Burn
Treatment Center, Upland, PA) within 72 hours of thermal burn injury between June 2009 to
January 2011 were evaluated for study eligibility. Patients who were clinically unstable or
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who had coincident non-burn injury were excluded, as were prisoners, pregnant patients,
patients with intentional injury, patients with a psychotic disorder, non-English speaking
patients, and patients with hepatic failure, renal failure, or a history of chronic opioid use
(defined as ≥ 20mg/day of oxycodone or equivalent). Also, because patients in this
observational study were subsequently to be evaluated for participation in a randomized
controlled medication trial, patients with greater than 20% total body surface area (TBSA)
burn, patients with an estimated hospital stay of <5 days or > 40 days, patients with greater
than first-degree atrioventricular block, patients taking a β-adrenergic antagonist medication,
and patients with asthma, diabetes, coronary artery disease, and congestive heart failure
were also excluded. Patients were also excluded who in the opinion of the investigators
would not provide reliable data. Local Institutional Review Board approval was obtained
from all study site IRBs.
Eligible patients were approached by research staff for study participation within 48 hours of
burn center admission. Written informed consent was obtained from all participants. Study
participation included blood sample collection for genetic analysis and completion of daily
pain symptom interviews on two consecutive days following enrollment. During each daily
pain symptom interview, participants were asked to rate their worst pain, their least pain,
and their average pain over the past 24-hours, as well as their pain upon waking. Each pain
assessment was performed using a verbal 0-10 numeric rating scale (NRS), where ‘0’ was
defined to the patient as ‘no pain’ and ‘10’; as ‘pain as severe as it could possibly be’. A
verbal NRS was used because it has been validated as a substitute for the Visual Analogue
Scale in acute care settings,17 and because it does not rely on upper extremity use to make a
precise mark on a scale. Daily pain symptom interviews which included the above
assessments were performed on two consecutive days, beginning on the day of enrollment.
For study analyses, our initial intention was to combine the two ratings of daily average pain
for each patient (one rating each day obtained on two consecutive days). However, as daily
pain symptom interviews were being conducted, it was observed that patients sometimes
provided an “average” pain rating greater than their worst reported pain or less than their
least reported pain. These observations, together with the high degree of educational
disadvantage in this population, lead us to appreciate that our study question (“Please rate
your average pain during the last 24 hours…”) was poorly designed for the study population
and (due to misunderstanding) did not yield valid data. Because of this, instead of using
average pain, we took advantage of the multiple different pain assessments available within
each individual (waking, worst, and least pain on two consecutive days) and created a
measure of overall pain burden using linear mixed modeling described below. This measure
of overall pain was used as the primary outcome measure for all analyses. Mean scores for
waking, worst, and least pain over two days were also obtained from this model.
Study participants received analgesics as per standard study site burn care; no changes were
made to the pain treatment of study participants. Information regarding medications received
during the two-day study period was extracted from the medical record. For each opioid
analgesic medication, total dose received during the two-day study period was calculated
and then multiplied by a conversion factor referenced to a 30 mg dose of morphine.18 These
doses were then summed to provide the total opioid dose (in morphine equivalents) received
by the patient during the two-day study period. Benzodiazepine conversions were similarly
calculated using a 10 mg diazepam reference.19 Demographic information was obtained
during the initial patient assessment via standardized questionnaire. Information regarding
patient burn characteristics was obtained from the medical record.
Blood samples were obtained for genetic analysis using an EDTA Vacutainer collection tube
(BD, Franklin Lakes, New Jersey, USA). DNA was purified from whole blood samples
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using the QIAamp DNA Mini Kit (QIAGEN, Valencia, California, USA) on the QIAcube
(QIAGEN), as per manufacturer's instructions. Genotyping was performed using a TaqMan
Allelic Discrimination Assay for rs4818 on the Bio-Rad CFX96 Real-time PCR Detection
System (Bio-Rad, Hercules, California, USA) at either the University of North Carolina
(Chapel Hill, NC) or Washington Hospital Center (Washington, DC). Patient DNA samples
were genotyped together with six HapMap CEU DNA samples (two of each genotype) and
two “no template” control samples.
When multiple disease susceptibility variants occur in the same gene, the overall functional
state of the gene may not be easily deduced from information regarding a single nucleotide
polymorphism (SNP).20 For this reason we used a haplotype-based approach to examining
COMT variants. In a previous study, three haplotypes located in the central COMT locus
accounted for approximately 96% of all haplotypes in this region and were associated with
variations in pain sensitivity15 and post traumatic pain.16 One of these haplotypes, the “low
pain sensitivity haplotype”, codes for high COMT enzyme activity and is associated with
relatively low pain vulnerability (i.e. is protective against pain).15 As in a previous study,16
we defined patients with no copies of this low pain sensitivity haplotype as having a
“COMT pain sensitive genotype”. Patients with a COMT pain sensitive genotype were
identified by genotyping SNP rs4818, because approximately 95% of individuals with a CC
genotype at rs4818 have a COMT pain sensitive genotype.15
Statistical analyses used linear mixed modeling to evaluate the association between COMT
pain vulnerable genotype and pain outcomes. Six pain measurements (waking, worst, and
least pain for day 1 and day 2) for each individual were entered into the model as a
correlated outcome variable. The correlations between pain measurements within each
individual were taken into account by specifying nested random effects for intercept. The
measure of overall pain was obtained as an adjusted least square mean pain score
incorporating waking, worst, and least pain for day 1 and day 2. Mean scores for waking,
worst, and least pain over two days were also obtained from this model. Age, gender, TBSA,
burn depth, and time from admission to pain assessment were considered as important
covariates and included in the model. In addition, because the frequency of genetic
variations can vary by ethnicity,21 associations between COMT pain vulnerable genotype
and pain outcomes were also adjusted for patient ethnicity (European American vs. African
American/Other). All analyses were conducted using SAS (version 9.2, SAS Institute Inc.,
Cary, NC). P-values < .05 were defined as statistically significant.
Results
Seventy-six patients were screened and determined to be eligible for study participation.
Fifty-seven (75%) of these patients consented to study participation. Among these patients,
the average number of days between burn injury and burn center admission was .6 days (.9),
and the average number of days between burn center admission and the beginning of the
two-day pain assessment period was 1.4 days (.9). Patient characteristics are shown in Table
1. Most patients were young European American males with partial thickness burn that was
≤ 10% TBSA. Median family income reported by study participants was $40,000-$60,000.
During the two-day study period, 100% (57/57) of participants received opioid analgesics,
11% (6/57) received benzodiazepines, and 2% (1/57) received nonsteroidal anti-
inflammatory drugs. Twenty-five (44%) participants had a COMT pain vulnerable genotype.
Patients with a COMT pain vulnerable genotype received more opioid and benzodiazepine
medications (mean morphine equivalent opioids 66.5±49.5 vs. 53.3±29.7, p=.247, mean
diazepam equivalent benzodiazepines 0.6±1.9 vs. 0.4±1.8, p=.804), although these
differences did not reach statistical significance.
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Associations between COMT genotype and patient pain experiences are shown in Table 2.
Despite receiving more opioid and benzodiazepine medication, individuals with a COMT
pain vulnerable genotype had significantly higher “least pain” scores and experienced
significantly higher pain on awakening. Overall pain (combination of least, worst, and
waking pain scores) was also significantly higher in patients with a COMT pain vulnerable
genotype. In contrast, no association was observed between COMT pain vulnerable
genotype and worst pain. These associations remained significant when adjusted for total
burn size, full thickness burn size, age, gender, ethnicity, and time from admission to study
assessment (Table 2).
Associations between selected patient characteristics and overall pain score are shown in
Table 3. Age, gender, total burn size, full thickness burn size, and type of thermal burn had
little influence on overall pain severity in our sample. Time from admission to pain
assessment was associated with overall pain severity at the trend level. The strength of
association between COMT pain vulnerable genotype and overall pain score exceeded that
of any other individual or burn characteristics assessed.
Discussion
In our sample, COMT pain vulnerable genotype predicted pain severity upon waking and
the least amount of pain that a burn patient experienced during a 24 hour period. In contrast,
no association was observed between COMT pain vulnerable genotype and the worst pain
that a burn patient experienced during a 24 hour period. This is likely due to a ceiling effect,
as ∼85% of patients reported a worst pain score ≥7. The presence or absence of a COMT
pain vulnerable genotype was a stronger predictor of overall pain severity (combination of
least, waking, and worst pain) in the early aftermath of burn injury than type of thermal
burn, size or depth of burn, or time from admission to pain assessment. Patients in the
sample with more severe pain received more opioid analgesics and more benzodiazepines,
indicating that increased pain scores were not the result of reduced pain medication
treatment.
While COMT pain vulnerable genotype influenced pain experiences after burn injury, it is
important that COMT genotype not be viewed as “the genetic determinant” of pain intensity
after burn injury. Indeed, the amount of variation in pain associated with the specific risk
genotype (genetic variant) assessed in this study is relatively modest. It is also important to
appreciate that the haplotypes used to define the genetic variant in this study are just a few
of a number of different genetic factors that may influence the function of the COMT
enzyme,22,23 and that the COMT enzyme in turn is just one of a great many biologic
components of catecholaminergic pathways. The primary utility of this preliminary study is
to suggest the potential value using genetic variants influencing components of biological
pathways related to catecholamines (and stress systems more broadly) to determine the
biologic pathways/mechanisms which most strongly influence post-burn pain.
This study identifies a specific link between individual variation in a genetic variant
influencing catecholamine metabolism (COMT pain vulnerable genotype) and pain after
burn injury. In the present sample, this genetic variant had more influence on burn pain than
burn injury characteristics. This finding is encouraging, as it suggests that novel treatments
which target relevant biologic pathways related to stress may have a substantial influence on
patient outcomes, even if the characteristics of the burn injury itself are immutable. This is
important, because burn-related pain is a major cause of morbidity among burn injury
survivors.24
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When interpreting our study results, several limitations should be considered. First, our
study included only thermal burn patients with TBSA burns ≤ 20%, and most patients in our
sample had burns that were less than 10% TBSA. However, such burn injuries constitute the
great majority (>86%) of admissions to major burn centers.25 The generalizability of our
findings to patients with larger burns or substantial third degree burns is unknown. Perhaps
more importantly, because patients in this observational study were subsequently to be
evaluated for participation in a randomized controlled medication trial, patients with greater
than first-degree atrioventricular block, patients taking a β-adrenergic antagonist medication,
and patients with asthma, diabetes, coronary artery disease, and congestive heart failure
were also excluded. Therefore the generalizability of study findings to these patient groups
cannot be assessed. Also, while our conclusions are valid regarding the relative influence of
COMT genotype vs. burn characteristics on burn-related pain in our sample, our results
should not be interpreted as evidence that other burn characteristics do not influence pain.
This is because our sample was small, and did not include the full range of burn injuries.
Finally, as described in the methods section, we erred when we assumed that patients would
be consistently familiar with the term “average”. Because of this, our overall pain score
combined waking pain, least pain, and worst pain, and actual differences regarding the
average, or typical, pain experiences of burn patients according to COMT genotype are
unknown. To prevent this error, future pain studies performed in burn centers should avoid
asking patients about their “average pain” (using instead pain “most of the time”, etc).
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Male (n,%) 45 (79)
Ethnicity (n,%)
 European American 39 (68)
 African American 15 (26)
 Other 3 (5)
Total body surface area (TBSA) of burn (n,%)
 1-5% 21 (37)
 6-10% 20 (35)
 11-15% 11 (19)
 16-20% 5 (9)
Total body surface area (TBSA) of burn that was 3rd Degree (n,%)
 0% 34 (60)
 1-5% 18 (32)
 6-10% 5 (9)
Type of thermal burn (n,%)
 Flame 26 (46)
 Grease 13 (23)
 Scald 14 (25)
 Contact 4 (7)
COMT pain vulnerable genotype* (n,%)
 Yes 25 (44)
 No 32 (56)
*
Defined as COMT genotype which does not contain 1 or more “low pain sensitivity” haplotypes.
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Table 3




 Male 6.0±.2 .305
 Female 6.5±.4
Age
 ≤40 years 6.0±.2 .878
 >40 years 6.2±.4
Ethnicity
 White 6.2±.2 .031
 Black 6.3±.4
 Other 4.2±.8
Time from admission to study assessment†
 ≤1 day 6.4±.3 .103
 >1 day 5.8±.3
Thermal burn type
 Flame 6.1±.3 .887
 Other 6.1±.3
Total Body Surface Area burned
 0-5% 6.3±.3 .544
 >5% 6.0±.2
Total Body Surface Area 3rd degree burned
 0% 5.9±.2 .254
 >0% 6.4±.3
COMT pain vulnerable genotype‡
 Yes 6.7±.3 .011
 No 5.7±.2
*
Linear mixed modeling was used to combine six pain measurements (waking, worst, and least pain assessed each day for two consecutive days)
for each individual into an overall pain score. See Methods for details.
†
Time elapse between admission for burn care and the first day of the two-day study period.
‡
Defined as COMT genotype which does not contain 1 or more “low pain sensitivity” haplotypes.
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